Year None2023202220212020201920182017 Phase 1 trial in progress of BXCL701 in AML: ASH 2023 December 9, 2023 Preclinical evidence that DPP8/9 inhibition is a critical determinant of BXCL701’s therapeutic benefit in combination with checkpoint inhibitor: SITC 2023 poster November 4, 2023 DPP9 overexpression as a potential predictive biomarker of response for BXCL701 + pembrolizumab in patients with SCNC: SITC 2023 Poster November 3, 2023 Phase 2 Updated efficacy results of BXCL701 + pembrolizumab in SCNC mCRPC: PCF 2023 Poster October 26, 2023 Phase 2 Updated efficacy results of BXCL701 + pembrolizumab in adenocarcinoma mCRPC: PCF 2023 Poster October 26, 2023 BXCL701-201 SCNC Poster ASCO GU 2023 February 16, 2023
Preclinical evidence that DPP8/9 inhibition is a critical determinant of BXCL701’s therapeutic benefit in combination with checkpoint inhibitor: SITC 2023 poster November 4, 2023
DPP9 overexpression as a potential predictive biomarker of response for BXCL701 + pembrolizumab in patients with SCNC: SITC 2023 Poster November 3, 2023
Phase 2 Updated efficacy results of BXCL701 + pembrolizumab in SCNC mCRPC: PCF 2023 Poster October 26, 2023
Phase 2 Updated efficacy results of BXCL701 + pembrolizumab in adenocarcinoma mCRPC: PCF 2023 Poster October 26, 2023
